Bosutinib and Phenobarbital interaction
Bosutinib and Phenobarbital: the Bosutinib prescribing label flags this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.
Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.
What the FDA labels say
From the Bosutinib (BOSULIF) label · effective 2026-03-10
• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF.
Strong CYP3A Inducers Avoid the concomitant use of strong CYP3A inducers with BOSULIF.
Concomitant use with a strong CYP3A inducer decreases bosutinib C max and AUC [see Clinical Pharmacology (12.3) ] which may reduce BOSULIF efficacy.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.